Core Viewpoint - On November 27, 2023, Huaren Health experienced a decline of 6.55% in stock price, with a trading volume of 811 million yuan, indicating market volatility and investor sentiment concerns [1]. Financing Summary - On the same day, Huaren Health had a financing buy-in amount of 73.29 million yuan and a financing repayment of 55.54 million yuan, resulting in a net financing buy of 17.75 million yuan [1]. - As of November 27, the total financing and securities balance for Huaren Health was 128 million yuan, which represents 5.27% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had a securities lending repayment of 0 shares and a securities lending sell of 100 shares, with a total sell amount of 1,626 yuan, reflecting limited short-selling activity [1]. Company Overview - Huaren Health, established on June 29, 2001, is located in Hefei, Anhui Province, and was listed on March 1, 2023. The company primarily engages in pharmaceutical agency, retail, and terminal procurement [1]. - The main revenue composition of Huaren Health is 97.60% from traditional Chinese and Western medicines, with the remaining 2.40% from other supplementary sources [1]. Financial Performance - For the period from January to September 2025, Huaren Health reported a revenue of 3.892 billion yuan, representing a year-on-year growth of 19.06%, and a net profit attributable to shareholders of 157 million yuan, which is a 45.21% increase compared to the previous year [2]. - As of September 30, 2025, the number of shareholders for Huaren Health was 20,100, a decrease of 22.86% from the previous period, while the average circulating shares per person increased by 29.64% to 7,422 shares [2]. Dividend and Institutional Holdings - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3]. - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth-largest circulating shareholder, holding 2.3203 million shares, an increase of 1.3357 million shares from the previous period [3].

Core Insights - The stock of Huaren Health experienced a decline of 0.87% on July 31, with a trading volume of 313 million yuan [1] - The company reported a financing buy-in amount of 22.32 million yuan and a net financing buy of 698,200 yuan on the same day [1] - As of July 31, the total financing and securities lending balance for Huaren Health was 139 million yuan, representing 6.26% of its market capitalization [1] Financing and Securities Lending - On July 31, Huaren Health had a financing buy-in of 22.32 million yuan, with a current financing balance of 139 million yuan, which is above the 90th percentile of the past year [1] - The securities lending data showed that on July 31, there were no shares sold short, and the securities lending balance was also zero, indicating a low level of short selling activity [1] Company Overview - Huaren Health, established on June 29, 2001, is located in Hefei, Anhui Province, and was listed on March 1, 2023 [1] - The company's main business segments include pharmaceutical agency, retail, and terminal procurement, with the revenue composition being 80.25% from Western and Chinese medicines, 4.62% from health products, and 4.00% from medical devices [1] Financial Performance - For the period from January to March 2025, Huaren Health achieved a revenue of 1.267 billion yuan, reflecting a year-on-year growth of 14.71% [2] - The net profit attributable to the parent company for the same period was 61.22 million yuan, representing a year-on-year increase of 28.15% [2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huaren Health increased by 9.39% to 18,000, while the average circulating shares per person decreased by 8.58% to 8,309 shares [2] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3] - Notably, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders as of March 31, 2025 [3]